Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Adv Ther · 2019 · PMC6824351 · PMID 30758745

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

also indirectly compared blinatumomab and InO and concluded that InO has a statistically significant advantage over blinatumomab with respect to remission and HSCT rate, and a favorable trend for EFS and long-term OS [ 15 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.